It’s only fair to share… DIMDAZENIL CAS 308239-86-3 WeightAverage: 372.81Monoisotopic: 372.1101515 Chemical FormulaC17H17ClN6O2 EVT-201, 308239-86-3, EVT201, 6J8AF7CLE4, EVT 201 7-Chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-methyl-6H-imidazo[1,5-a] [1,4]benzodiazepin-6-one 7-chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc. Dimdazenil, sold under …
Tag «Insomnia»
Daridorexant
It’s only fair to share… Daridorexant Molecular FormulaC23H23ClN6O2 Average mass450.921 Da [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- ACT-541468, , Nemorexant FDA APPROVED 2022, 1/7/2022, To treat insomnia, Quviviq Daridorexant HCl CAS#: 1792993-84-0 (HCl) Chemical Formula: C23H24Cl2N6O2 Molecular Weight: 487.39 Elemental Analysis: C, 56.68; H, 4.96; Cl, 14.55; N, 17.24; O, 6.57 Methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)-, hydrochloride (1:1) Daridorexant HCl; Daridorexant hydrochloride; …
Nemorexant
It’s only fair to share… Nemorexant ACT-541468, UNII LMQ24G57E9 [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] LMQ24G57E9 Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- Originator Actelion Pharmaceuticals Developer Idorsia Pharmaceuticals Class Sleep disorder therapies Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists Phase III Insomnia 19 Oct 2018 Idorsia Pharmaceuticals plans a phase I trial for Liver disorders (Hepatic impairment) in November 2018 (PO) (NCT03713242) 09 Oct …